Focused On-demand Library for Leiomodin-2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6P5Q4

UPID:

LMOD2_HUMAN

Alternative names:

Cardiac leiomodin; Leiomodin

Alternative UPACC:

Q6P5Q4; A4D0W9; A4D0Y2; Q8WVJ8

Background:

Leiomodin-2, also known as Cardiac leiomodin, plays a pivotal role in heart muscle function. It mediates the nucleation of actin filaments, promoting actin polymerization, essential for normal sarcomere organization and heart function. This protein's involvement in regulating actin filament length underscores its significance in maintaining cardiac muscle structure and contractility.

Therapeutic significance:

Leiomodin-2's critical role in heart function is underscored by its association with Cardiomyopathy, dilated, 2G, a severe condition leading to early-onset heart failure. Understanding the role of Leiomodin-2 could open doors to potential therapeutic strategies for treating heart diseases, particularly those involving sarcomere organization and actin filament regulation.